| Source publication date | (updated; first published 2025-09-10) |
|---|---|
| Reported on Testosterone Science | |
| Outlet type | Testosterone and hormone clinic or telehealth website |
| Population | Men |
| Source | Hims |
| URL | hims.com/blog/is-enclomiphene-fda-approved (opens in a new tab) |
Specific Claim Evaluated
Unlike testosterone therapy, enclomiphene does not suppress sperm production and may even help preserve or improve fertility.
Primary Research Supporting or Contradicting the Claim
In phase 3 trials, enclomiphene maintained sperm concentration in the normal range over 16 weeks while testosterone gel reduced it; no fertility or pregnancy outcomes were measured (Kim et al., 2016).
Corrected Evidence-Based Interpretation
Enclomiphene preserves sperm concentration over months in men with secondary hypogonadism, but there is no evidence that it improves fertility outcomes, and it is not FDA approved.
Rationale for Grade
The page states the regulatory history accurately but presents preservation of a semen parameter as preservation or improvement of fertility. This extends the trial end point to a clinical outcome that was not studied, and the publisher sells the product.
References
- Kim ED, McCullough A, Kaminetsky J. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement. BJU Int. 2016;117(4):677-685. PMID
Supporting excerpt: "Enclomiphene citrate treatment maintained sperm concentrations in the normal range."